Valuation: Orexo AB

Market Cap 849M 87.84M 76.75M 70.48M 65.73M 125M 8.36B 127M 329M 4.1B 330M 323M 14.13B P/E 2026 *
-2.69x
P/E 2027 * -3.37x
Enterprise Value 651M 67.34M 58.84M 54.03M 50.39M 95.53M 6.41B 97.14M 252M 3.14B 253M 247M 10.84B EV / Sales 2026 *
25x
EV / Sales 2027 * 26.2x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day+2.97%
1 week+2.10%
Current month+1.25%
1 month+23.98%
3 months+9.21%
6 months-25.12%
Current year-19.27%
1 week 23
Extreme 23
25.45
1 month 18.58
Extreme 18.58
25.45
Current year 17.52
Extreme 17.52
36
1 year 17.5
Extreme 17.5
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-04
Director of Finance/CFO 59 2022-08-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 64 2001-12-31
Director/Board Member 70 2019-04-10
Director/Board Member 62 2022-03-31
Date Insider Type Main position Quantity % Market Cap.
25-09-03Free

Chief Executive Officer

1,393 0.0040%
25-09-03Buy

Chief Executive Officer

6 0.0000%
25-09-02Free 149 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+2.97%+2.10%+20.90%+133.65% 84.79M
+3.34%+3.28%+57.25%+12.28% 310B
+2.08%+0.34%+30.88%-2.67% 71.56B
+3.17%+9.38%+47.57%+120.27% 9.13B
+1.98%+5.16%+7.50%-0.17% 8.27B
-0.12%-2.26%-5.87%+7.05% 4.38B
-1.10%+8.65%+18.27%+39.91% 4.21B
-0.57%-1.68%-34.24%+21.86% 3.39B
+1.35%+7.37%+49.83%+59.85% 2.75B
-1.31%+4.21%+17.92%-21.65% 2.24B
Average +1.17%+6.01%+21.00%+37.04% 41.57B
Weighted average by Cap. +2.94%+3.55%+49.43%+12.29%

Financials

2026 *2027 *
Net sales 26M 2.69M 2.35M 2.16M 2.01M 3.82M 256M 3.88M 10.08M 126M 10.11M 9.89M 433M 27M 2.79M 2.44M 2.24M 2.09M 3.96M 266M 4.03M 10.46M 130M 10.49M 10.27M 450M
Net income -322M -33.33M -29.12M -26.74M -24.94M -47.28M -3.17B -48.08M -125M -1.56B -125M -122M -5.36B -259M -26.81M -23.43M -21.51M -20.06M -38.03M -2.55B -38.67M -100M -1.25B -101M -98.47M -4.31B
Net Debt -198M -20.49M -17.91M -16.44M -15.34M -29.07M -1.95B -29.56M -76.73M -957M -76.95M -75.28M -3.3B -142M -14.7M -12.84M -11.79M -11M -20.85M -1.4B -21.2M -55.03M -686M -55.19M -53.99M -2.36B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
65
Date Price Change Volume
26-07-02 SEK 24.30 +2.97% 18,971
26-07-01 SEK 23.60 -1.67% 13,849
26-06-30 SEK 24.00 -1.64% 28,864
26-06-29 SEK 24.40 -0.41% 61,679
26-06-26 SEK 24.50 +2.94% 40,731
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise